Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The impact of immuno-oncology on ALL outcomes

Talha Badar • 2 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the impact of immuno-oncology on acute lymphoblastic leukemia (ALL) outcomes, highlighting agents such as blinatumomab and inotuzumab ozogamicin. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Talha Badar

TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
2:36
TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
Talha Badar • 7 Dec 2025
Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms
3:06
Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms
Talha Badar • 7 Dec 2025
Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
4:03
Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
Talha Badar • 7 Dec 2025
Blinatumomab vs inotuzumab ozogamicin for ALL
4:38
Blinatumomab vs inotuzumab ozogamicin for ALL
Talha Badar • 2 Jun 2020

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals